JP7186702B2 - 神経系の疾患及び障害を治療するための方法並びに組成物 - Google Patents

神経系の疾患及び障害を治療するための方法並びに組成物 Download PDF

Info

Publication number
JP7186702B2
JP7186702B2 JP2019531607A JP2019531607A JP7186702B2 JP 7186702 B2 JP7186702 B2 JP 7186702B2 JP 2019531607 A JP2019531607 A JP 2019531607A JP 2019531607 A JP2019531607 A JP 2019531607A JP 7186702 B2 JP7186702 B2 JP 7186702B2
Authority
JP
Japan
Prior art keywords
dreadd
seq
disorder
agonist
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531607A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019526630A5 (https=
JP2019526630A (ja
Inventor
ボウリー，ハンナ，イー．
アストン－ジョーンズ，ギャリー
Original Assignee
ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー filed Critical ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー
Publication of JP2019526630A publication Critical patent/JP2019526630A/ja
Publication of JP2019526630A5 publication Critical patent/JP2019526630A5/ja
Application granted granted Critical
Publication of JP7186702B2 publication Critical patent/JP7186702B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
JP2019531607A 2016-08-31 2017-08-31 神経系の疾患及び障害を治療するための方法並びに組成物 Active JP7186702B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662381883P 2016-08-31 2016-08-31
US62/381,883 2016-08-31
PCT/US2017/049629 WO2018045178A1 (en) 2016-08-31 2017-08-31 Methods and compositions for treating diseases and disorders of the nervous system

Publications (3)

Publication Number Publication Date
JP2019526630A JP2019526630A (ja) 2019-09-19
JP2019526630A5 JP2019526630A5 (https=) 2020-10-08
JP7186702B2 true JP7186702B2 (ja) 2022-12-09

Family

ID=61301702

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531607A Active JP7186702B2 (ja) 2016-08-31 2017-08-31 神経系の疾患及び障害を治療するための方法並びに組成物

Country Status (5)

Country Link
US (2) US11542315B2 (https=)
EP (1) EP3507371B1 (https=)
JP (1) JP7186702B2 (https=)
AU (1) AU2017321708B2 (https=)
WO (1) WO2018045178A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018064465A1 (en) 2016-09-29 2018-04-05 The Regents Of The University Of California Compounds for increasing neural plasticity
EP3773723A1 (en) * 2018-04-13 2021-02-17 BlumenTech S.L. Combination product for the induction and/or maintenance of general anesthesia
KR20210050493A (ko) * 2018-05-25 2021-05-07 더 칠드런스 메디칼 센터 코포레이션 척수 손상의 치료 방법
JP2022512622A (ja) * 2018-10-05 2022-02-07 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション 改変受容体を含む血小板の作製方法及びその使用法
CN113784962B (zh) 2019-02-27 2025-04-25 加利福尼亚大学董事会 用于治疗脑部疾病的氮杂环庚三烯并-吲哚类和其他杂环
AU2020228289B2 (en) 2019-02-27 2026-02-05 The Regents Of The University Of California N-substituted indoles and other heterocycles for treating brain disorders
GB202002073D0 (en) * 2020-02-14 2020-04-01 Ucl Business Ltd Horizontal cells
WO2022097764A1 (ko) * 2020-11-04 2022-05-12 전남대학교병원 프레가발린 및 티아넵틴을 포함하는 신경병성 통증 치료용 약학적 조성물
JP2024519329A (ja) 2021-05-12 2024-05-10 ユーシーエル ビジネス リミテッド 合成受容体
WO2023278295A1 (en) 2021-06-29 2023-01-05 The Broad Institute, Inc. Compositions and methods for ameliorating anterodorsal thalamus hyperexcitability
TW202333668A (zh) 2021-12-15 2023-09-01 美商德利克斯醫療公司 經苯氧基及苄氧基取代之精神成形素(psychoplastogen)及其用途
US11980603B2 (en) 2022-06-11 2024-05-14 AMS Therapeutics, LLC Method of treating expressive language deficit in autistic humans
WO2024182608A2 (en) * 2023-03-01 2024-09-06 Gateway Biotechnology, Inc. Chemogenetics-based therapy for neurological disorders
TWI883819B (zh) * 2024-02-06 2025-05-11 陸汝斌 組合物用於製備改善認知能力之藥物的用途
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105533A2 (en) 2008-02-19 2009-08-27 The Johns Hopkins University Methods for predicting esophageal adenocarcinoma (eac)
WO2016161124A1 (en) 2015-03-31 2016-10-06 New York University Compositions and method for reducing seizures
WO2017049252A1 (en) 2015-09-17 2017-03-23 Switch Bio, Inc. Compositions and methods for treating neurological disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003214920A1 (en) * 2002-02-04 2003-09-02 Millennium Pharmaceuticals Inc. Methods and compositions for treating hematological disorders
GB201404470D0 (en) 2014-03-13 2014-04-30 Ucl Business Plc Therapeutic methods and materials
JP6968331B2 (ja) * 2016-03-09 2021-11-17 アサフ，ファディ ニューロン性疾患の治療におけるニューロン調節のためのｄｒｅａｄｄの使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009105533A2 (en) 2008-02-19 2009-08-27 The Johns Hopkins University Methods for predicting esophageal adenocarcinoma (eac)
WO2016161124A1 (en) 2015-03-31 2016-10-06 New York University Compositions and method for reducing seizures
WO2017049252A1 (en) 2015-09-17 2017-03-23 Switch Bio, Inc. Compositions and methods for treating neurological disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Current Biology, 2016.7, Vol.26, pp.2358-2363, Supplemental Information
Gene, 1998, Vol.211, pp.63-69
Molecular Neurodegeneration, 2015, Vol.10, #47
The Journal of neuroscience, 2015, Vol.35, No.4, pp.1343-1353
日本老年医学会雑誌, 1985, Vol.22, No.1, pp.40-46

Also Published As

Publication number Publication date
EP3507371A1 (en) 2019-07-10
US20190194287A1 (en) 2019-06-27
EP3507371A4 (en) 2020-08-05
WO2018045178A1 (en) 2018-03-08
AU2017321708A1 (en) 2019-03-14
AU2017321708B2 (en) 2024-01-04
US11542315B2 (en) 2023-01-03
JP2019526630A (ja) 2019-09-19
US20230174613A1 (en) 2023-06-08
EP3507371B1 (en) 2026-01-28
CA3035203A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
JP7186702B2 (ja) 神経系の疾患及び障害を治療するための方法並びに組成物
Griebel et al. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?
Sahenk et al. AAV1. NT-3 gene therapy for Charcot–Marie–Tooth neuropathy
Boyden et al. Mutations in the satellite cell gene MEGF10 cause a recessive congenital myopathy with minicores
US10801040B2 (en) Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the peripheral nervous system of a subject
US20160272973A1 (en) Methods and compositions employing an osteopontin aptamer to deliver nucleic acids into smooth muscle, endothelial, cardiac and progenitor/stem cells
US11753639B2 (en) Micro-RNA and obesity
US12571027B2 (en) Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
Almutiri et al. Non-viral-mediated suppression of AMIGO3 promotes disinhibited NT3-mediated regeneration of spinal cord dorsal column axons
Liu et al. Gadd45b mediates axonal plasticity and subsequent functional recovery after experimental stroke in rats
CA2999279A1 (en) Targeted expression of chloride channels and methods of use thereof
CN111956658A (zh) miRNA 148簇作为诊断和/或治疗认知障碍相关疾病标志物的应用
US6025193A (en) Methods and compositions for diagnosis and treatment of pathological conditions related to abnormal dopamine receptor expression
US20220380777A1 (en) Exon skipping of fc-epsilon-ri-beta and ms4a6a in combination for the treatment of allergic diseases
CN113398244B (zh) 一种治疗帕金森病的制剂及其应用
Schultz et al. Reduction of retinal ganglion cell death in mouse models of familial dysautonomia using AAV-mediated gene therapy and splicing modulators
JP2003520784A (ja) 神経障害を治療するためのインスリン様増殖因子ｉイソ型ｍｇｆの使用
US20220372492A1 (en) Compounds for modulating fc-epsilon-ri-beta expression and uses thereof
KR20210039495A (ko) 피드백이 가능한 합성 유전자, 표적 시드 매치 카세트, 및 그 용도
JP2007521333A (ja) 中枢神経系の活動を調節するための組成物および方法
CA3035203C (en) Methods and compositions for treating diseases and disorders of the nervous system
Beard et al. Evaluation of neuroretina following iv or intra‐CSF AAV9 gene replacement in mice with MPS IIIA, a childhood dementia
US20100286248A1 (en) Human fg01 gene and its applications
Freret et al. Understanding vision loss from optic pathway glioma in neurofibromatosis type 1
CN121695274A (zh) 抑郁症的治疗方法和药物组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200825

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210824

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220704

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221101

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221129

R150 Certificate of patent or registration of utility model

Ref document number: 7186702

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250